drugset / Trial / NCT02155673
A Phase 2 Extension Study of Study GCS-100-CS-4002
RandomizedParallel-groupSingle-blindTreatment
Summary
The primary objective of this study is to determine the safety and tolerability of extended dosing of GCS-100 in patients with CKD.
Timeline
- Start
- 2014-01
- Primary completion
- 2016-05
- Completion
- 2016-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GCS-100 | Unknown | 1.5 mg/m2 | Intravenous |
| Subject | GCS-100 | Unknown | 30 mg/m2 | Intravenous |